BioPharma Resources

Drug Trial Radar · NCT02795260

Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65(III-healthy)

Phase III Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65,Adopting Randomized Blinded and Parallel Controlled Method

Last checked: Nov 19, 2026Latest source record: Oct 1, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,802 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,802

Actual

Start

May 2016

Primary completion

Oct 2016

Study completion Oct 2016

Sponsor

Sponsor type
Industry
Collaborators
Air Force Military Medical University, China; Proswell Medical Corporation; Jiangsu Province Centers for Disease Control and Prevention; Jurong Centers for Disease Control and Prevention
First posted
Jun 10, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The investigators recruit about 1800 cases participants who has signed ICF,then do some physical examinations for these people, including ecg, X-ray, HIV,blood pressure, specific gamma-interferon detection ,collection of medical history and the like .These subjects who meet the standard are considered as study population I. Population I are injected intradermally with ESAT6-CFP10 and Tuberculin purified protein derivative(TB-PPD) at different arm of the same subject and get at least 360 participants whose three kinds of detection result are all negative and are considered as study population II.Then,they are immune to the Bacillus Calmette -Guerin(BCG) vaccine or the placebo of the BCG.Do specific gamma-interferon detection before the skin test,then inject intradermally with ESAT6-CFP10 and TB-PPD at different arm of the same subject 12 weeks after immunity.

Conditions

  • Tuberculosis

Interventions

  • Bacillus Calmette - GuerinBiological

    The participants are injection intradermally with 0.1ml ESAT6-CFP10(EC) in the right OR left arm and TB-PPD in the other arm(right OR left) after 12 weeks immunization of BCG .

  • placebo of Bacillus Calmette - GuerinBiological

    The participants are injection intradermally with 0.1ml ESAT6-CFP10(EC) in the right OR left arm and TB-PPD in the other arm(right OR left) after 12 weeks immunization of placebo of BCG .

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of study population III Negative for Reaction at 24 hours After intradermal injection with EC or TB-PPDTime frame: At 24 hours after Intradermal injection with EC or TB-PPD
  2. Number of study population III Negative for Reaction at 48 hours After intradermal injection with EC or TB-PPDTime frame: At 48 hours after Intradermal injection with EC or TB-PPD

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.